Read today’s Kaiser Health News
In other news:
About pharma
Lilly, Superluminal ink $1.3B pact targeting hard-to-crack GPCRs: Eli Lilly will pay Superluminal Medicines up to $1.3 billion under a collaboration to discover and develop small-molecule drugs for cardiometabolic diseases and obesity.
The deal gives Lilly exclusive rights to compounds arising from the alliance, which focuses on undisclosed G protein-coupled receptor (GPCR) targets, a class long considered challenging to drug. GPCRs play central roles in a range of biological processes, but their structural complexity has stymied past drug discovery efforts.
Eli Lilly ramps up UK price of weight loss jab Mounjaro after Trump demands: Eli Lilly said Thursday that it would increase the prices of medicines in Europe and other developed markets “in order to make them lower” in the U.S., in an apparent response to the Trump administration’s calls to do so. It singled out the list price of its popular weight-loss drug in the U.K. as part of that effort.
About healthcare personnel
9 generational trends shaping hospital workforce planning FYI (Really worth reading)